EyePoint Reports Q1 2026 Earnings and Clinical Progress
EyePoint (EYPT) reported Q1 2026 earnings with a net loss of $85 million, driven by increased operating expenses from ongoing Phase III trials. The company's cash and investments stood at $223 million, projected to fund operations through 2027. Clinical progress in the DURAVYU program for wet AMD showed a low trial discontinuation rate and positive data safety monitoring.
Tickers: $EYPT
Topics: biotech clinical trials financials pharma